Monday 16 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.44
0.15
−4.18%
Follow KYNB
Alert me
Ratios over time Q3 FY25 to Q2 FY26
Returns on capital
ROIC was 0.0% in Q2 FY26, the highest of these four quarters.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|
| ROE | −189.9% | −165.2% | −144.0% | −157.8% |
| ROIC | 0.0% | 0.0% | 0.0% | 0.0% |
Debt
Net debt is 5.17× a year’s EBITDA. Debt is 0.00× equity.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.0× | 0.0× | 0.0× | 0.0× |
| Net debt / EBITDA | 22.6× | 6.6× | 6.2× | 5.2× |
Cash cycle, in days
Customers pay in 27 days, inventory is held 285 days and suppliers are paid in 633. Suppliers fund 321 days of working capital.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|
| Cash cycle | 86 | 11 | 106 | −321 |
| Days to pay suppliers | −334 | 2458 | 422 | 633 |
| Days to be paid | 5 | 12 | 247 | 27 |
Per share, from Q3 FY25
Since Q3 FY25, per share: revenue has fallen 44.4%.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|
| Revenue | 1.0× | 0.8× | 0.9× | 0.6× |
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.23 | 0.19 | 0.17 | 0.17 |
P/S ratio |
5.97 | 5.51 | 3.69 | 6.62 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(26.82) | (1.94) | (1.98) | (7.66) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
9.49 | 14.55 | 11.74 | 18.71 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.65) | (19.62) | (4.09) | (2.27) | |
EV/FCF |
(4.66) | (19.47) | (4.08) | (2.27) | |
Quick Ratio |
3.28 | 3.05 | 3.28 | 2.54 | |
Current Ratio |
3.71 | 3.39 | 3.61 | 2.69 | |
Net Debt/EBITDA |
22.61 | 6.55 | 6.23 | 5.17 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.04 | 0.04 | 0.05 | 0.03 | |
Operating CF/Net income |
(0.01) | 1.29 | 0.91 | (0.33) | |
Capex/Depreciation |
(0.05) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(2.60) | (5.61) | (5.69) | (7.42) | |
Research and Development Expense of Revenue |
112.36% | 569.15% | 202.41% | (462.75%) | |
Selling, General and Administrative Expense of Revenue |
492.10% | 567.82% | 156.82% | (628.63%) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
61.52% | 93.11% | 30.79% | (66.76%) | |
Graham Net Nets |
(0.15) | (1.06) | (1.42) | (1.11) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
436.57% | 517.88% | 596.76% | 600.00% | |
Free Cash Flow Yield |
(34.08%) | (13.56%) | (78.06%) | (124.63%) | |
Revenue per Share |
0.27 | 0.32 | 0.92 | (0.36) | |
Operating CF per Share |
(0.46) | (4.53) | (3.43) | (0.99) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.46) | (4.53) | (3.43) | (0.99) | |
Cash per Share |
29.17 | 22.01 | 21.56 | 22.56 | |
Shareholders Equity per Share |
(0.99) | (4.21) | (7.60) | (7.32) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.99) | (4.21) | (7.60) | (7.32) | |
Free Cash Flow |
(1.86) | (18.33) | (13.89) | (3.99) | |
Working Capital |
97.45 | 69.83 | 73.24 | 60.79 | |
Capital Expenditures |
(0.01) | 0.00 | — | — | |
Net Current Asset Value |
(7.59) | (37.53) | (39.04) | (33.88) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.58 | 0.35 | 2.59 | 0.24 | |
Average Payables |
7.17 | 4.40 | 6.19 | 8.99 | |
Average Inventory |
13.90 | 3.45 | 3.27 | 3.62 | |
Average Assets |
200.72 | 167.06 | 137.42 | 139.57 | |
Average Common Equity |
(113.59) | (111.06) | (113.59) | (116.07) |
Columns are period end dates · fundamentals updated 25 Oct 2026